摘要
目的探讨选择性环氧合酶-2(COX-2)抑制剂塞来昔布对SGC-7901人胃癌细胞及裸鼠移植瘤的生长、端粒酶活性及相关因素的影响,研究其抗肿瘤的作用机制。方法终浓度为100,200,及300μmol/L的塞来昔布作用于SGC-7901人胃癌细胞,同时建立裸鼠胃癌模型,20只裸鼠随机分为两组,对照组隔日腹腔注射生理盐水,塞来昔布组隔日腹腔注射塞来昔布30mg/kg,采用MTT比色法测定胃癌细胞的生长抑制率,采用半定量-TRAP银染法检测SGC-7901人胃癌细胞及裸鼠移植瘤组织中的端粒酶活性。结果不同浓度的塞来昔布对SGC-7901人胃癌细胞的生长均有抑制作用,抑制率与对照组相比,差异有显著性(P<0.05);塞来昔布组裸鼠肿瘤生长明显受抑制,抑瘤率为61.3%,与对照组相比,差异有显著性(P<0.05);同时塞来昔布也显著抑制SGC-7901人胃癌细胞及裸鼠移植瘤组织中的端粒酶活性,其抑制作用呈时间-剂量依赖性。结论塞来昔布通过降低端粒酶活性,诱导细胞凋亡,抑制细胞增殖,从而参与抑制胃癌生长,这可能是COX-2抑制剂体内抗胃癌的机制之一。
Objective To study the effects of celecoxib,a selective COX-2 inhibitor,on cell proliferation and telomerase activi- ty in SGC-7901 human gastric cancer cell line and mice xenograft to explore its anti-neoplasm mechanism. Methods MTT assay was used to determine cell proliferation after incubation in different concentrations （100,200,300 μmol/L） of celecoxib. Twenty mice xenograft models with SGC-7901 human gastric cancer cell were established and randomly divided into two groups. The mice of treated groups were administered with selective COX-2 inhibitor celecoxib. Telomerase activity was detected by semi-TRAP assay. Results Celecoxib inhibited significantly the growth of SGC-7901 human gastric cancer cells and xenograft. It elevated the inhibit- ing rate（P 〈 0.05）as compared with control groups. The telomerase activity was significantly inhibited in SGC-7901 human gastric cancer cells and xenngraft in dose and time dependent manner. Conclusion COX-2 inhibitor celecoxib inhibited telomerase activity, induced apoptosis and inhibited proliferation,The results indicate one of the mechanisms underlying the anti-cancer effect of COX-2 inhibitor.
出处
《实用癌症杂志》
2006年第2期113-116,共4页
The Practical Journal of Cancer
基金
青岛市卫生局科研基金资助(2004-wszd005)
